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The product of a tree (Tabebuia avellanedae) from South
America,  β-lapachone, is known to exhibit various
pharmacological properties, the mechanisms of which are
poorly understood. The aim of the present study was to
further elucidate the possible mechanisms by which β-
lapachone exerts its anti-proliferative action in cultured
human prostate cancer cells. We observed that the
proliferation-inhibitory effect of β-lapachone was due to
the induction of apoptosis, which was confirmed by
observing the morphological changes and cleavage of the
poly(ADP-ribose) polymerase protein. A DNA flow
cytometric analysis also revealed that β-lapachone
arrested the cell cycle progression at the G1 phase. The
effects were associated with the down-regulation of the
phosphorylation of the retinoblastoma protein (pRB) as
well as the enhanced binding of pRB and the transcription
factor E2F-1. Also, β-lapachone suppressed the cyclin-
dependent kinases (Cdks) and cyclin E-associated kinase
activity without changing their expressions. Furthermore,
this compound induced the levels of the Cdk inhibitor
p21
WAF1/CIP1 expression in a p53-independent manner, and
the p21 proteins that were induced by β-lapachone were
associated with Cdk2. β-lapachone also activated the
reporter construct of a p21 promoter. Overall, our results
demonstrate a combined mechanism that involves the
inhibition of pRB phosphorylation and induction of p21 as
targets for β-lapachone. This may explain some of its anti-
cancer effects.
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Introduction
β-Lapachone (3,4-dihydro-2,2-dimenthyl-2H-napthol[1,2-b]
pyran-5,6-dione) is a naturally occurring plant quinone that is
obtained from the bark of the lapacho tree (Tabebuia
avellanedae), which is native to South America (Schaffner-
Sabba  et al., 1984). This compound inhibits reverse
transcriptase and DNA polymerase-α, and blocks DNA repair
that sensitizes tumor cells to DNA-damaging agents (Boorstein
and Pardee, 1984; Schaffner-Sabba et al., 1984; Boothman et
al., 1989). Several studies suggested that β-lapachone could
directly target DNA topoisomerases and inhibit their activity,
which would result in cytotoxicity (Li et al., 1993; Frydman et
al., 1997; Li et al., 2000; Pardee et al., 2002). However, its
inhibitory mode is distinct from that of other typical
topoisomerase inhibitors, such as camptothecin and its related
compounds (Li et al., 1993). β-lapachone exhibits other
pharmacological actions. These include anti-bacterial, anti-
fungal, and anti-trypanocidal actions (Lopes et al., 1978;
Goijman and Stoppani, 1985; Guiraud et al., 1994), which are
linked to the formation of reactive oxygen species (Cruz et al.,
1978; Docampo et al., 1979). In addition, it has been known
that  β-lapachone induces apoptotic cell death in human
leukemia and the prostate cancer cell line in a p53-independent
pathway, which implicated its potential clinical utility against
both cancers (Li et al., 1995; Planchon et al., 1995). Vanni et al.
(1998) reported that the cytotoxic effects of β-lapachone are
related to the reduced enzymatic activity of poly(ADP-ribose)
polymerase (PARP). This suggests that the inhibition of PARP
plays a central role in the complex biological effects that are
induced by β-lapachone. Recently, the inhibition of the nuclear
transcription factor-κB and activator protein-1 activity by β-
lapachone explained some of its pharmacological effects as
novel targets for β-lapachone (Manna et al., 1999). However,
the molecular mechanisms of its anti-proliferative action on cell
growth are not completely known.
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The present study was carried out to characterize the
probable mechanisms that are involved in the β-lapachone-
mediated growth inhibitory effect in human prostate
carcinoma cells. We demonstrated that β-lapachone induced
cell cycle arrest at the G1 phase, and apoptosis through a
combined mechanism that involved the down-regulation of
the phosphorylation of pRB and the induction of the Cdk
inhibitor p21.
Materials and Methods
Cell culture and β-lapachone The human prostate carcinoma
PC-3 cells were cultured in a RPMI 1640 medium (Gibco BRL,
Gaithersburg, USA), as previously described (Choi et al., 1997). β-
Lapachone was purchased from Biomol (Plymouth Meeting, USA)
and dissolved in ice-cold absolute alcohol as a stock solution at a 10
mM concentration. It was stored in aliquots at −20
oC.
Growth study and morphology For the growth inhibition
analysis, the cells were cultured in the absence or presence of β-
lapachone for 6 h. After an additional 24 h of culture in a normal
medium, the cells were trypsinized, washed with phosphate-
buffered saline (PBS), and the viable cells were scored with a
hemacytometer through exclusion of trypan blue. For the
morphological study, the cells were grown on a coverslip and
treated with β-lapachone for 6 h. They were Wright-stained (Fisher
Scientific, Pittsburgh, USA) after 24 h, as recommended by the
manufacturer.
Cell cycle analysis The cells were trypsinized, washed with PBS,
and fixed in 75% ethanol at 4
oC for 30 min. Prior to the analyses,
the cells were again washed with PBS, suspended in a cold
propidium iodide (PI, Sigma Chemical Co., St. Louis, USA)
solution (Choi et al., 2000; Shim et al., 2002), and incubated at
room temperature in the dark for 30 min. Flow cytometry analyses
were performed on a FACScan flow cytometry system (Becton
Dickinson, San Jose, USA).
Nuclear staining with DAPI The cells were washed with PBS
and fixed with 3.7% paraformaldehyde in PBS for 10 min at room
temperature. The fixed cells were washed with PBS, and stained
with a 4,6-diamidino-2-phenylindole (DAPI, Sigma, St. Louis,
USA) solution for 10 min at room temperature. The cells were
washed two more times with PBS and analyzed via a fluorescence
microscope.
Immunoprecipitation and Western blot analysis The total cell
lysates were lysed in an extraction buffer as previously described
(Choi et al., 1997). For immunoprecipitation, the cell extracts were
incubated with an immunoprecipitating antibody or normal rabbit
serum in an extraction buffer for 1 h at 4
oC. The immuno-complex
was collected on protein A-Sepharose beads (Sigma) and separated
by a SDS-polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes (Schleicher & Schuell, Keene, USA). A
Western blot analysis was performed, as described (Choi et al.,
1997), using the enhanced-chemiluminescence (ECL) detection
system (Amersham Corp., Arlington Height, USA). The polyclonal
antibodies to cyclin E, Cdk2, Cdk4 and monoclonal anti-E2F-1, and
monoclonal antibodies to pRB and p21 were obtained from Santa
Cruz Biotechnology Inc. (Santa Cruz, USA) and Upstate
Biotechnology (Lake Placid, USA), respectively. The monoclonal
anti-PARP antibody was purchased from Calbiochem (Cambridge,
USA). The peroxidase-labeled secondary antibodies were
purchased from Amersham.
In vitro immuno-complex kinase assay Whole cell lysates were
incubated with a primary antibody, precipitated, and resuspended in
a kinase assay mixture buffer (Choi et al., 2000; Kim et al., 2001)
that contained [γ-
32P] ATP (ICN, Irvine, USA) and histone H1
(Sigma, St. Louis, USA) as a substrate. After incubation at 37
oC for
30 min, the reaction was stopped by the addition of the same
amount of 2 × SDS sample buffer. After boiling and spinning, the
samples were separated on 10% SDS-polyacrylamide gels, dried,
and bands were detected by autoradiography.
p21 promoter-luciferase construct and transfection assay The
cells were transiently co-transfected with the full-length 2.4-kb
human p21 promoter-luciferase reporter construct (Choi et al.,
2000) and the β-galactosidase reporter vector pCMBβ (Promega,
Madison, USA) using the LipofectAMINE transfection reagent
(Gibco BRL), according to the manufacturers recommendations.
Following transfection, the cells were incubated for 12 h, the
medium was exchanged, and the cells were incubated in the
presence or absence of β-lapachone. The cells were then lysed, and
the luciferase activity in the lysates was assayed using a Dynatech
ML1000 luminometer (Dynatech Laboratories, Chantilly, USA).
The luciferase activity was normalized to β-galactosidase activity,
which was assayed using the β-galactosidase enzyme assay system
(Promega, Madison, USA).
Results
Growth inhibition by β-lapachone To evaluate the effect
of β-lapachone on cell proliferation, we initially determined
the effects of β-lapachone on the growth of human prostate
carcinoma PC-3 cells. As shown in Fig. 1A, β-lapachone had
a strong inhibitory effect on cell proliferation in a
concentration-dependent manner (about a 55% decrease from
the baseline in the presence of 3 µM β-lapachone). Analyses
of the cell cycle distribution of cells after exposure to β-
lapachone showed that these cells had a marked accumulation
in the percentage of cells in the G1 phase of the cell cycle
(Fig. 1B). This was accompanied by a significant decrease in
their G2/M phase when compared with the untreated control
cells, which suggests that the growth inhibitory effect of β-
lapachone was the result of a block during this G1 phase.
Also, these cells did not enter the S phase.
Morphological changes and apoptotic cell death induced
by β-lapachone An analysis by light microscopy showed
that the β-lapachone-treated cells showed a distinct
morphological change. The β-lapachone-treated cells wereβ-Lapachone-induced Apoptosis and G1 Arrest 225
variable in size, with protuberances that resulted in more of a
spindle shape, membrane shrinking, and cell rounding up
(Fig. 2A). Moreover, the percentage of apoptotic sub-G1 cells
increased in a time-dependent manner (Fig. 1B). Therefore,
we investigated whether β-lapachone could induce apoptosis
in PC-3 cells using DAPI staining and PARP cleavage. The
control cells displayed an intact nuclear structure, while cells
that were treated with β-lapachone had chromosomal
condensation and formation of apoptotic bodies, which
indicated that β-lapachone induced apoptotic cell death (Fig.
2B). A Western blot analysis showed that the β-lapachone
treatment induced the degradation of the PARP protein and
accumulation of the 85 kDa in β-lapachone-treated cells (Fig.
2C). These results, therefore, indicate that the growth
Fig. 1. Growth inhibition and cell cycle arrest by β-lapachone in PC-3 cells. (A) The cells were plated at 0.5 × 10
4 cells per 100-mm
plate and incubated for 24 h. The cells were treated with β-lapachone at 1 µM, 3 µM, and 6 µM concentrations for 6 h, and then the
media were changed. After a 24 h incubation in a normal medium, the cell number was determined by hemacytometer counts of the
trypan blue-excluding cells. Each bar represents the mean number of triplicate determinations. Values from each treatment were
expressed as a percent relative to the control (100%). Bars represent the mean +/- SD. (B) Exponentially-growing cells were treated at
0 time with 2 µM β-lapachone. A flow cytometric cell cycle analysis was performed, comparing the untreated controls with the cells
that were treated with β-lapachone for the indicated time. Arrows mean the portions of apoptotic cells, sub-diploid cells.
Fig. 2. β-lapachone-induced morphological changes and apoptosis in PC-3 cells. (A) The cells were incubated with 3 µM and 6 µM β-
lapachone for 6 h. After a 24 h incubation in a normal medium, the cells were sampled, stained with Wright dye, and examined under
light microscopy. Magnification, x 200. (B) The untreated control cells and β-lapachone-treated cells with β-lapachone for 6 h were
harvested after a further 24 h culture, spun down, and stained with a DAPI solution (1 µg/ml). After a 10 min incubation at room
temperature, the cells were washed with PBS and photographed with a fluorescence microscope using a blue filter. Magnification,
x 400. (C) Total cell lysates from the untreated control and the cells that were treated with β-lapachone were prepared and subjected to
8% SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Western blot was detected with an antibody
against PARP and ECL detection.226 Yung Hyun Choi et al.
inhibition that was observed in response to β-lapachone is due
to either a growth arrest of the cells or apoptotic cell death.
Down-regulation of pRB phosphorylation and increased
binding of pRB and E2F-1 by β-lapachone Since  β-
lapachone arrests cells in the G1 phase (as assessed by DNA
flow cytometry), then the RB gene product pRB is an
important checkpoint protein in the G1 phase of the cell cycle.
We next determined the kinetics between the phosphorylation
of pRB and the transcription factor E2F-1. The total levels of
the pRB expression decreased remarkably, and changed from
the hyperphosphorylated form to the hypophosphorylated
form by the β-lapachone treatment (Fig. 3A). The association
of pRB and E2F-1 was almost undetectable by a co-
immunoprecipitation analysis of the untreated log phase cells.
However, there was a strong increase in the association of
pRB and E2F-1 in the β-lapachone-treated cells (Fig. 3B),
which suggests that β-lapachone inhibits the releasing of the
E2F-1 protein from pRB.
β-Lapachone down-regulates Cdks and cyclin E-
dependent kinase activity We next tested whether β-
lapachone altered the expression levels of the G1 regulatory
proteins. As demonstrated in Fig. 4A, it did not affect the
protein levels of Cdk2, Cdk4, and cyclin E. However, as
shown in Figure 4B, the kinase activity of these proteins was
significantly inhibited in response to β-lapachone in a
concentration-dependent manner. These results suggest that
the suppressive effect of β-lapachone on the cell growth of the
PC-3 cells was partly caused by down-regulating the activity
of Cdks and the cyclin E-associated kinase without altering
the expression of their proteins.
β-Lapachone induces the Cdk inhibitor p21 protein and
enhanced association of p21 with Cdk2 To understand the
molecular mechanism by which β-lapachone down-regulates
Cdks and the cyclin E-dependent kinase activity, we
investigated whether the Cdk inhibitors were involved in the
β-lapachone-induced growth arrest in PC-3 cells. In the
untreated control cells, the expression of the p21 protein was
undetectable. However, incubation of the cells with β-
lapachone caused a striking dose- and time-dependent
increase that was blocked by actinomycin D (Fig. 5A, B and
C); whereas, β-lapachone did not affect the expression of
other Cdk inhibitors, including p27 and p16 (data not shown).
In addition, the association of p21 with Cdk2 was not detected
in the untreated control cells. However, treatment of the cells
with  β-lapachone resulted in a significant increase in the
binding of p21 and Cdk2 (Fig. 5D), which suggests that the
down-regulation of the Cdks kinase activity by β-lapachone is
mainly caused by the interaction between Cdk2 and the
highly-induced p21.
Fig. 3. Hypophosphorylation of pRB and enhanced association
of pRB and E2F-1 in PC-3 cells after exposure to β-lapachone.
The untreated control cells and β-lapachone-treated cells with β-
lapachone for 6 h were harvested after a further 24 h culture.
(A) Total cell lysates were prepared and separated by 8% SDS-
polyacrylamide gel. Western blotting was performed using anti-
pRB and ECL detection. (B) Whole cell lysates (0.5 mg of
protein) from the control cells and the cells that were treated
with  β-lapachone were immunoprecipitated with an anti-E2F-1
antibody. Immuno-complexes were separated by 8% SDS-
polyacrylamide gel electrophoresis, transferred to a nitrocellulose
membrane, and probed with an anti-pRB antibody. Proteins were
detected by ECL detection.
Fig. 4. Effects of β-lapachone on the protein levels of Cdk2, Cdk4, and cyclin E, and their kinase activities in PC-3 cells. (A) Total cell
lysates were prepared and subjected to 10% SDS-polyacrylamide gels, and transferred to nitrocellulose membranes. Western blots were
detected with the indicated antibodies, and ECL detection. (B) Total cell lysates (0.5 mg protein) from the control cells and the cells
that were treated with β-lapachone were immunoprecipitated with anti-Cdk2, anti-Cdk4, or anti-cyclin E antibody. Kinase activity was
assayed using histone H1 as substrates. Phosphorylated histone H1 (H1) was analyzed by a 10% SDS-polyacrylamide gel electrophoresis
and autoradiography.β-Lapachone-induced Apoptosis and G1 Arrest 227
β-Lapachone induces the activation of the p21 promoter
Since the p21 expression is markedly induced by β-lapachone,
we subsequently investigated if the up-regulation of the p21
expression involves the transcriptional regulation of the p21
gene promoter. As shown in Fig. 6, following exposure to β-
lapachone, the p21 promoter construct was significantly
activated in a concentration- and time-dependent manner up to
a 18 h exposure. As the p53 gene is deleted in PC-3 cells
(Kozlowski et al., 1984; Rubin et al., 1991), our data indicated
that β-lapachone arrests the cell cycle at the G1 phase, in part
through the induction of p21 in a p53-independent manner.
Discussion
We tested β-lapachone for its activity in inhibiting the growth
of human prostate carcinoma PC-3 cells. We found that
treatment of the cells with β-lapachone resulted in a
concentration-dependent inhibition of cell viability (Fig. 1A),
which was associated with gross morphological changes.
Subsequent experiments addressed the issue of whether this
compound agitates the cell cycle (using a DNA flow
cytometric analysis) and induces apoptosis (using Western
blotting for PARP cleavage and DAPI staining). Flow
cytometric data of the β-lapachone-treated cells clearly
revealed a cell-cycle block at the G1 to S phase transition and
an accumulation of cells at the sub-G1 apoptotic region (Fig.
1B), which contained less DNA than the G1 cells (Evans,
1993; Loo and Rillema, 1998). Furthermore, chromatin
condensation and proteolytic cleavage of PARP were
observed after the treatment of β-lapachone (Fig. 2B and C),
which indicates the occurrence of apoptotic cell death (Evans,
1993; Loo and Rillema, 1998; Scovassi et al., 1998). These
results suggest that β-lapachone interferes with proliferation
and induces apoptosis in close association with the G1 arrest
by modulation of cell cycle-regulatory proteins and associated
kinase activities as a possible molecular mechanism of the
effect of β-lapachone. Therefore, we investigated the effects of
β-lapachone on the expression of G1/S transition regulatory
proteins to analyze the mechanism of the G1 arrest. As shown
in Fig. 3A, we found that there was a loss of phosphorylated
pRB protein by treatment with β-lapachone and a marked
binding of pRB and E2F-1 in response to the β-lapachone
treatment (Fig. 3B). This indicates that β-lapachone indirectly
inhibited the transcriptional activity of the E2F family for the
S phase entry (DeGregori et al., 1995; Weinberg, 1995; Sidle
Fig. 5. Induction of Cdk inhibitor p21, and enhanced association of p21 with Cdk2 in PC-3 cells after exposure to β-lapachone. (A and
B) The cells were treated with β-lapachone at 1 µM, 3 µM, and 6 µM concentrations for 6 h, then further cultured in a normal medium
for 24 h, or the cells were treated with 2 µM β-lapachone for the indicated time. (C) The cells were incubated with 2 µM β-lapachone
(β-lapa), 100 µg/µl actinomycin D (Acti-D), or β-lapachone plus actinomycin D for 24 h. (D) The cells were treated with 2 µM  β-
lapachone for 24 h. The cell lysates were immunoprecipitated with an anti-Cdk2 antibody or normal rabbit serum (NRS), and
immunoprecipitates were collected. Equal amounts of whole proteins or immunoprecipitated proteins were separated by 12% SDS-
polyacrylamide gels, transferred to nitrocellulose membranes, and probed with an anti-p21 antibody. The proteins were detected by ECL
detection.
Fig. 6. Activation of p21 promoter-luciferase fusion plasmids in
PC-3 cells after exposure to β-lapachone. The p21 promoter
construct fused to the luciferase gene, and the β-galactosidase
reporter vectors were transiently co-transfected into cells. The
cells were treated with different concentrations of β-lapachone
for 6 h and further cultured in a normal medium for 24 h (A), or
the cells were treated with 2 µM  β-lapachone for the indicated
time (B). Luciferase activities, which were normalized to the β-
galactosidase enzyme assay system, were expressed as fold
increase from the control. The results are expressed as the mean
± SD of data from two separate experiments.228 Yung Hyun Choi et al.
et al., 1996). The results from the in vitro kinase assay
demonstrated that β-lapachone inhibits Cdks and the cyclin E-
dependent activity, rather than altering these protein levels
(Fig. 4), which plays an essential role in cell cycle progression
at the G1 to S phase transition stage (Matsushime et al., 1992;
Koff  et al., 1992). These results were consistent with the
effective concentration and time that could significantly
induce the growth inhibition, cell cycle arrest, and apoptosis.
Furthermore, we assumed that the down-regulation of Cdks
and cyclin E-dependent kinase activity as well as the cell cycle
arrest by β-lapachone may be also involved by an additional
inhibitory mechanism (s). To elucidate this hypothesis, we
next investigated whether Cdk inhibitors (such as p21, p27,
and p16) are involved in the β-lapachone-induced growth
arrest using Western blotting and co-immunoprecipitation
analysis. This hypothesis was clearly supported by the
following facts: (1) β-lapachone selectively induced the
expression of the Cdk inhibitor p21 protein, which was
blocked by the transcription inhibitor actinomycin D. (2) The
increased p21 proteins by the β-lapachone treatment were
tightly associated with Cdk2. (3) β-lapachone activated the
p21 promoter-luciferase fusion plasmids (Fig. 6). These
results demonstrate that the down-regulations of Cdks and the
cyclin E-dependent kinase activity are mainly caused by
selective induction of the p21 expression, and further indicate
that β-lapachone regulates the transcriptional level of the p21
expression. Even though p21 was first identified as a tumor
suppressor p53-inducible gene, it has also been shown to
mediate the induction of cell cycle arrest at the G1 phase after
DNA damage (El-Deiry et al., 1993; Xiong et al., 1993;
Waldman et al., 1995). Also, p21 can be induced in a p53-
independent mechanism in various cell lines that are
stimulated for growth arrest, differentiation, and apoptosis
(Datto  et al., 1995; Zeng and El-Deiry, 1996; Vogt et al.,
1997; Choi et al., 2000). Because the p53 gene is truncated
and the p53 protein is absent in PC-3 cells (Kozlowski et al.,
1984; Rubin et al., 1991) that were used in this study, the
present data clearly demonstrate that β-lapachone is regulating
the level of the p21 expression through a p53-independent
pathway.
In summary, we have addressed that β-lapachone strongly
inhibits cell proliferation and induces apoptosis in the human
prostate carcinoma PC-3 cells. These results provide
convincing evidence that β-lapachone exerts its effect on cell
cycle progression of PC-3 cells by two pathways. First, by a
significant decrease in the phosphorylated forms of tumor
suppressor pRB that lead to its inhibitory effect of the E2F-
dependent transcriptional activity of the genes that control the
transition from the G1 to S phase and subsequent DNA
synthesis. Second, by an increase in the p21 expression that
leads to its increased binding with cyclin/Cdk complexes,
which results in a marked decrease in their kinase activities.
When these results are compared with those that were
obtained for the growth study and cell cycle phase distribution
following the β-lapachone treatment of PC-3-M cells, it can
be suggested that the p53-independent regulation of p21 could
be the major cause of the effect of β-lapachone on the G1
arrest and anti-proliferative response.
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